Analysis of Long Non-Coding RNA (lncRNA) uc.38 and uc.63 Expression in Breast Carcinoma Patients.
breast cancer
lncRNA
transcribed-ultra conserved regions
uc.38
uc.63
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
18
02
2022
revised:
21
03
2022
accepted:
25
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Background. The role of the transcribed ultra-conserved regions (T-UCRs) has not yet been fully discovered, but the studies showed some indications that impaired expression of T-UCRS were present in malignant tumors, including breast cancer. Aim. The presented work assessed the expression of two transcribed-ultra conserved regions−uc.63 and uc.38−in breast cancer tissue samples. Material and methods. The research was carried out on a group of 100 patients with invasive ductal carcinoma and 100 patients (test group) with benign tumors in breast tissue (control group). Results. As a result of the statistical analysis, it was shown that the expression of uc.63 and uc.38 is statistically significant, and, accordingly, higher (p < 0.0001) and lower (p < 0.0001) in the test group than in the control group. Statistical dependency analysis of the expression of uc.63 and uc.38 and the selected clinical and pathological factors showed that the expression of uc.63 statistically drops with the patient’s age (p = 0.04), and is higher in the breast cancer tissue type M1 according to the TNM classification (p = 0.036) and in tissues with overexpressed HER2 (p = 0.035). Conclusion. The obtained results of the statistical analysis indicate a relationship between the expression of uc.63 and uc.38 and the occurrence of breast cancer.
Identifiants
pubmed: 35456414
pii: genes13040608
doi: 10.3390/genes13040608
pmc: PMC9031052
pii:
doi:
Substances chimiques
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Carcinogenesis. 2009 Mar;30(3):544-5; author reply 546
pubmed: 19126653
Mol Ther Nucleic Acids. 2018 Sep 7;12:359-369
pubmed: 30195774
Mol Oncol. 2013 Feb;7(1):1-13
pubmed: 23218182
Am J Cancer Res. 2020 May 01;10(5):1568-1591
pubmed: 32509398
Lancet Oncol. 2012 Nov;13(11):1141-51
pubmed: 23084519
J Glob Oncol. 2018 Jul;4:1-16
pubmed: 30085889
Oncogene. 2010 Jun 17;29(24):3583-92
pubmed: 20383195
Nat Commun. 2014 Dec 19;5:5812
pubmed: 25524025
Cancers (Basel). 2019 Nov 14;11(11):
pubmed: 31739537
Asian Pac J Cancer Prev. 2016;17(S3):43-6
pubmed: 27165206
Am J Cancer Res. 2017 Dec 01;7(12):2438-2451
pubmed: 29312798
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506
pubmed: 26359465
Int J Mol Sci. 2019 Oct 06;20(19):
pubmed: 31590453
Acta Pharm Sin B. 2021 Feb;11(2):340-354
pubmed: 33643816
Oncol Res. 2016;23(5):205-17
pubmed: 27098144
BMC Genomics. 2015;16 Suppl 7:S5
pubmed: 26100984
Front Genet. 2020 Jun 30;11:550
pubmed: 32714364
Breast Cancer Res Treat. 2002 Mar;72(2):107-15
pubmed: 12038701
Oncotarget. 2017 May 30;8(22):35669-35680
pubmed: 27447964
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
FASEB J. 2020 Dec;34(12):15630-15646
pubmed: 33058262
Exp Mol Pathol. 2003 Jun;74(3):336-40
pubmed: 12782023
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
Med Sci (Paris). 2008 Aug-Sep;24(8-9):725-30
pubmed: 18789219
Cancer Invest. 1988;6(3):245-54
pubmed: 3167610
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445129
Breast Cancer Res Treat. 2011 Aug;128(3):855-61
pubmed: 21331621
Vet Pathol. 2014 Jul;51(4):759-74
pubmed: 24045890
Carcinogenesis. 2008 Feb;29(2):351-5
pubmed: 18174240
Cells. 2019 Sep 01;8(9):
pubmed: 31480503